17 GHP Healthcare and Pharmaceutical Awards 2026 MC is a global pharma services company that partners with small to mid-sized biotech and pharma companies across the full product lifecycle - from early-stage clinical development through to market access and drug commercialization in the EU and UK. The company’s particular focus is on complex therapeutic areas: rare diseases, complex oncology, and advanced therapeutic modalities, including cell and gene therapies. What sets TMC apart is the depth and practicality of the support it provides. Rather than offering one-size-fits-all solutions, TMC’s services are organised into three specialist divisions, each focused on a distinct phase of the development journey: • TMC Consulting delivers expert-led strategic and operational consultancy across regulatory affairs, clinical development, pharmacovigilance, medical services, and quality management. • TMC Clinical specialises in early-phase clinical development, combining the responsiveness of a specialist pharma services company with the expertise of a clinical research organisation (CRO). • TMC Commercial provides flexible, full-service drug commercialization solutions in the EU and UK - from marketing authorization submissions through to post-approval obligations. “Our strategic intent is to offer solutions to small/mid-sized biotech and pharma companies that speed up all stages of development and commercialization, ensuring patients can get faster access to innovative treatments.” At the heart of TMC’s delivery model is its global Associates network - a framework that distinguishes the company in a crowded market. TMC’s Associates are senior subject-matter experts, each with a minimum of 15 years’ experience in their respective field, deployed across more than 70 countries worldwide. Many are multilingual; all bring on-the-ground knowledge of local regulatory environments combined with the consistency of a global operating framework. For resource-conscious biotech and emerging pharma companies, this model solves a practical problem: access to the right expertise at the right moment, without the fixed costs of building large permanent teams. As Simon explains: “We provide the right-sized support that evolves with your program - from early development through to commercialization and post-authorization.” Senior Associates work directly alongside TMC’s in-house team on client programs, ensuring accountability, continuity, and expert Drug development is rarely straightforward - and for small to mid-sized biotech and pharma companies working in rare disease, complex oncology, and advanced therapeutics, the pressure to move fast without compromising quality or compliance can feel relentless. Since its inception in 2000, TMC Pharma Services has built its reputation on partnering with its clients to accelerate drug development timelines and bring lifechanging therapies to patients faster, all while retaining control of their assets. CEO Simon Estcourt tells us more. Rare Disease CRO of the Year 2026 input from the outset. The result is premium-quality delivery with greater cost control and budget predictability - a combination that matters enormously to companies managing lean internal resources against ambitious timelines. Over the past 12 months, TMC has supported a number of strategically significant programs across rare disease, complex oncology, and advanced therapeutic modalities. The projects spans the breadth of the company’s capabilities - navigating scientific, regulatory, and operational complexity to keep development moving forward. “The progress across these projects has been significant,” Simon told us, “with a clear focus on accelerating development timelines while maintaining rigorous quality and compliance standards. Our collaborative approach ensures that we are not only advancing programs efficiently but, ultimately, helping to bring transformative therapies to patients faster.” From its unrivalled expertise to its distinctive Associates business model, TMC has established itself as a key player on the global drug development stage. The company has played an instrumental role in advancing timelines and ensuring that small to medium-sized companies can access the right development solution at critical points in their product lifecycle. For its significant contributions to the field, TMC has been rightfully named the Rare Disease CRO of the Year 2026. As TMC builds on this momentum, Simon reflects on what the recognition means and where the company is headed: “Receiving this recognition is genuinely meaningful to our team - it reflects the dedication, expertise, and care that our people bring to every program they work on. But for us, it’s also a reminder of what drives us: the patients at the end of every development timeline we help accelerate. As we look ahead, our focus remains on deepening our specialist capabilities, expanding our global Associates network, and continuing to help small to mid-sized biotech and pharma companies navigate the complexities of drug development.” Contact: Sharon Campion Company: TMC Pharma Services Ltd Web Address: www.tmcpharma.com T Jul23706
RkJQdWJsaXNoZXIy MTUyMDQwMA==